|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/395 | |||
| A61P 35/02 |
| (11) | Patento numeris | 2197918 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 08785642.3 |
| Europos patento paraiškos padavimo data | 2008-08-20 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-06-23 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-12-18 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2008/006833 |
| Data | 2008-08-20 |
| (87) | Numeris | WO 2009/030368 |
| Data | 2009-03-12 |
| (30) | Numeris | Data | Šalis |
| 07017337 | 2007-09-05 | EP |
| (72) |
FRIESS, Thomas, DE
KLEIN, Christian, CH
UMANA, Pablo, CH
|
| (73) |
F. Hoffmann-La Roche AG,
Grenzacherstra e 124, 4070 Basel,
CH
Roche Glycart AG, Wagistrasse 18, 8952 Schlieren-Zuerich, CH |
| (54) | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES |
| COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES |